Compare DLB & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLB | LEGN |
|---|---|---|
| Founded | 1965 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.9B |
| IPO Year | 2005 | 2020 |
| Metric | DLB | LEGN |
|---|---|---|
| Price | $66.47 | $21.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $93.60 | $69.58 |
| AVG Volume (30 Days) | 657.1K | ★ 2.6M |
| Earning Date | 01-28-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.62 | N/A |
| Revenue | ★ $1,349,130,000.00 | $909,045,000.00 |
| Revenue This Year | $5.03 | $68.83 |
| Revenue Next Year | $4.02 | $51.27 |
| P/E Ratio | $25.29 | ★ N/A |
| Revenue Growth | 5.92 | ★ 74.75 |
| 52 Week Low | $64.02 | $21.19 |
| 52 Week High | $89.66 | $45.30 |
| Indicator | DLB | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 25.47 |
| Support Level | $65.96 | $21.19 |
| Resistance Level | $67.60 | $28.97 |
| Average True Range (ATR) | 1.21 | 1.27 |
| MACD | -0.02 | -0.26 |
| Stochastic Oscillator | 16.33 | 9.13 |
Dolby Laboratories Inc. develops technologies that enhance audio and video capture, transmission, and playback, enabling high-quality experiences across movies, TV, music, sports, and more. The company designs and manufactures audio, imaging, accessibility, and related hardware and software mainly for cinema, including digital cinema servers and media encryption and packaging tools. It generates the majority of its revenue by licensing its technology, brand, and patents to device manufacturers and by selling cinema hardware and services. It operates as a single reportable segment, with revenue derived mainly from licensing and, to a lesser extent, from premium cinema technologies, across the United States and international markets.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.